(919) 237-4897 info@t3dtherapeutics.com

Presentations & Publications


2016 – 9th Clinical Trials in Alzheimer’s Disease Conference Oral Presentation, San Diego, CA – OC39 – Cognitive Improvement in Mild to Moderate Alzheimer’s Patients: Final Results of an Open Label, Phase 2A Study of T3D-959 – Download PDF

2016 – Alzheimer’s Association International Conference Poster Presentation Toronto – Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer’s Patients Treated with T3D-959: Interim Results of a Phase 2a Open Label Clinical Trial – Download PDF

2015 – CED Life Science Conference 2015 Showcase Oral Presentation, Raleigh, NC – View Video


2017 – De la Monte SM, Tong M, Didsbury J (2017) Improved Brain Insulin/IGF Signaling and Decreased Neuro-inflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer’s Disease. J Alzheimers Dis. 55:849-864. – https://www.ncbi.nlm.nih.gov/pubmed/27802237

2016 – Tong M, DeochandC, Didsbury J, de la Monte SM (2016) T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer’s Disease. J Alzheimers Dis 51, 123-138. – https://www.ncbi.nlm.nih.gov/pubmed/26836193

2016 – Tong M, Dominguez C, Didsbury J, de la Monte SM. (2016) Targeting Alzheimer’s Disease Neuro-metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. J Alzheimers Dis Parkinsonism 6:238. doi: 10.4172/2161-0460.1000238 – Download PDF